Related Experiment Video

Updated: Aug 13, 2026

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Fibroblast growth factor receptor-2 mutation analysis in human prostate cancer

P Mehta1, C N Robson, D E Neal

  • 1School of Surgical Sciences, The Medical School, University of Newcastle, Newcastle upon Tyne, UK.

BJU International
|November 9, 2000
PubMed
Abstract

Insights

Mutations in the fibroblast growth factor receptor-2 (FGFR2) gene are not common in prostate cancer. This study found no FGFR2 mutations in tumor samples or prostate cell lines, suggesting they do not drive cancer development.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Fibroblast Growth Factor Receptor-2 (FGFR2) plays a role in cell growth.
  • The IIIb variant of FGFR2 specifically binds FGF7/KGF, an androgen-inducible factor crucial for prostate growth.
  • Understanding FGFR2's role may reveal new therapeutic targets for prostate cancer.

Purpose of the Study:

  • To investigate the association between mutations in key regions of the FGFR2 gene and prostate cancer development.
  • To screen for FGFR2 mutations in prostate tumor samples, adjacent tissues, and cell lines.

Main Methods:

  • Screening of FGFR2 gene hot-spots (exons encoding IIIa, IIIb, IIIc, and TMD) using Single-Strand Conformational Polymorphism-Polymerase Chain Reaction (SSCP-PCR) and cycle-sequencing.
  • Analysis of 30 prostate cancer patients' tumor samples and 11 blood samples.
  • Examination of human prostate cell lines (LNCaP, PC3, DU145, PNT1A, PNT1B) and tumor foci.

Main Results:

  • Established positive controls with known FGFR2 mutations confirmed the validity of the SSCP-PCR and sequencing methods.
  • No polymorphisms or mutations were detected in the analyzed FGFR2 regions (IIIa, IIIb, IIIc, and TMD) across all examined prostate tumor samples and cell lines.

Conclusions:

  • Mutations within the FGF binding domain and Transmembrane Domain (TMD) of FGFR2 are infrequent in human prostate cancer.
  • The findings suggest that FGFR2 mutations are not a common driver in the pathogenesis of prostate cancer.

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...